• Tags: glaucoma
Simple OCT rule helps cut glaucoma false positives in myopia
Research

Simple OCT rule helps cut glaucoma false positives in myopia

Expert-derived OCT interpretation rules offer a practical way to reduce false-positive glaucoma diagnoses in myopic eyes.
SpyGlass Pharma reports 4-year, FIH data on BIM-IOL System
Pipeline

SpyGlass Pharma reports 4-year, FIH data on BIM-IOL System

Company is continuing phase 3 enrollment while working with the FDA toward a future NDA submission.
Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery
Research

Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery

Latest 3-month data demonstrate clinically meaningful IOP reductions compared to cataract surgery alone.
SpyGlass Pharma unveils positive 12-month data on BIM-IOL System
Research

SpyGlass Pharma unveils positive 12-month data on BIM-IOL System

Interim findings offer a closer look at the safety and efficacy of the bimatoprost drug pad-intraocular lens system for OAG and OHT.
New data supports omega-3s for glaucoma in DED patients
Research

New data supports omega-3s for glaucoma in DED patients

Patients had roughly half the 5-year risk of developing glaucoma, though investigators stop short of claiming cause and effect.
FDA grants IDE approval to Ciliatech for glaucoma implant study
Pipeline

FDA grants IDE approval to Ciliatech for glaucoma implant study

Clearance brings company closer to a clinical and regulatory pathway for the cilioscleral interpositioning device, designed to lower IOP in POAG.
FDA accepts Nicox's NDA for IOP-lowering glaucoma drop
Pipeline

FDA accepts Nicox's NDA for IOP-lowering glaucoma drop

PDUFA target action date of April 30, 2027, is set for the newly-renamed K-911, a nitric oxide-donating bimatoprost formulation.
New research confirms association of OSA with glaucoma
Research

New research confirms association of OSA with glaucoma

Real-world cohort study indicates patients with obstructive sleep apnea may have a higher long-term risk of developing glaucoma.
Side sleepers face higher risk of uneven glaucoma
Research

Side sleepers face higher risk of uneven glaucoma

Reduced ONH blood flow in the dependent eye during side sleeping may help explain asymmetric damage in patients with obstructive sleep apnea.
Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study
Pipeline

Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study

US 510(k) study to evaluate glaucoma drainage device for IOP reduction among OAG patients who failed previous medical and surgical treatment.
Kowa submits NDA for NCX 470, a IOP-lowering glaucoma drop
Pipeline

Kowa submits NDA for NCX 470, a IOP-lowering glaucoma drop

Pending FDA review, Nicox’s NO-donating bimatoprost formulation could receive approval and commercially launch by the end of 2027.
Glaucoma risk higher among women with postmenopausal HRT
Research

Glaucoma risk higher among women with postmenopausal HRT

Postmenopausal hormone therapy may be linked to higher glaucoma risk, with registry data suggesting the association holds across hormone types.
Thea Pharma's ZOLYMBUS ophthalmic gel launches for glaucoma management
Products

Thea Pharma's ZOLYMBUS ophthalmic gel launches for glaucoma management

The PF formulation debuts 9 months after securing FDA approval with a patented mucoadhesive lubricating gel technology for IOP reduction.
Should normal-tension glaucoma patients be more closely monitored?
Research

Should normal-tension glaucoma patients be more closely monitored?

New research suggests certain NTG patients may need closer follow-up due to unstable visual field results.
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System
Products

SpyGlass Pharma: New add-on CPT code supports BIM-IOL System

AMA approves application in conjunction with Category I cataract surgery codes; applies to investigational bimatoprost delivery system for IOP reduction in OAG and OHT.
FDA clears Balance Ophthalmics' wireless-enabled IOP device for glaucoma
Products

FDA clears Balance Ophthalmics' wireless-enabled IOP device for glaucoma

Next-generation iteration of the portable IOP-lowering system delivers patient usage data to clinical practices from nighttime monitoring.
Registration opens for Eyes On Glaucoma 2026
Events

Registration opens for Eyes On Glaucoma 2026

The largest virtual glaucoma event of the year offers up to 5 hours of free CE from leading clinical experts in the industry.
Bayer to acquire Perfuse Therapeutics, expanding ophthalmic pipeline
Business

Bayer to acquire Perfuse Therapeutics, expanding ophthalmic pipeline

Deal includes the biotech’s investigational sustained-release implant currently in phase 2 clinical trials for glaucoma and diabetic retinopathy.
Iantrek introduces AlloSpan Canal to its bio-interventional platform
Products

Iantrek introduces AlloSpan Canal to its bio-interventional platform

Tech combines nitinol-guided canaloplasty with allogeneic biological scaffolding to restore and maintain Schlemm’s canal—without leaving synthetic hardware in the eye.
Study: Smoking an unlikely risk factor for glaucoma
Research

Study: Smoking an unlikely risk factor for glaucoma

While the association between smoking and glaucoma was weak, smoking cessation remains important for well-being.